Recent developments include a private stock offering in February 2026 to raise working capital and an amendment to an asset purchase agreement with R.J. Reynolds Vapor Company in May 2025 involving the sale of synthetic nicotine products.

• In February 2026, Charlie's Holdings completed a private offering issuing 3,550,000 shares of common stock at $0.20 per share, raising proceeds for working capital purposes [S18].
• In May 2025, the company amended an asset purchase agreement with R.J. Reynolds Vapor Company, selling three additional synthetic nicotine products and related assets for $1.5 million, increasing total assets sold to fifteen products [S21].
• The company continues to defend its PMTAs against FDA Marketing Denial Orders, with judicial stays currently in place allowing continued marketing of affected products pending litigation [S1].

The company has demonstrated revenue growth from $7.8 million in 2024 to $20.9 million in 2025 and achieved net income of $4.5 million in 2025, indicating operational progress. Successful defense and potential approval of PMTAs could enable continued marketing of key products. The company’s ability to raise capital through private offerings supports working capital needs. Strategic asset sales to established industry players like R.J. Reynolds Vapor Company may provide liquidity and focus. Continued product innovation and market acceptance could enhance revenue and profitability.

The company faces significant regulatory risks including FDA Marketing Denial Orders and the need for PMTA approvals, which could restrict product marketing and materially impact revenue. Reliance on third-party manufacturers introduces operational risks including production delays and quality control issues. Intense competition from larger, better-funded companies may limit market share and pricing power. The company has experienced negative cash flow from operations despite reported net income, raising concerns about cash flow sustainability. Limited trading liquidity and potential dilution from outstanding preferred stock and options may affect shareholder value.

Charlie's Holdings operates in a niche vapor and synthetic nicotine market characterized by significant regulatory barriers and evolving consumer preferences. Its moat is limited by reliance on third-party manufacturers, lack of internal manufacturing capacity, and intense competition from larger, well-funded companies including established tobacco firms. The company's proprietary product formulations are protected primarily through trade secrets and trademarks rather than patents, which may limit defensibility. Regulatory approvals such as PMTAs present both barriers to entry and risks to ongoing operations. Overall, the company's competitive advantages are constrained by market and regulatory challenges.

• Regulatory Risks: The company’s products are subject to extensive FDA and other regulatory requirements, including PMTA approvals. Marketing Denial Orders and potential flavor bans pose material risks to product availability and revenue.
• Operational Risks: Dependence on third-party contract manufacturers creates risks of production delays, quality control failures, and increased costs.
• Market and Competitive Risks: The company operates in a niche, evolving market with intense competition from larger tobacco and vapor product companies, which may limit growth and profitability.
• Financial Risks: Despite reported net income, the company has used cash in operating activities, indicating cash flow challenges. Limited liquidity and potential dilution from outstanding securities pose financial risks.
• Personnel Risks: Loss of key management personnel or failure to attract qualified staff could adversely affect operations and growth.
• Cybersecurity Risks: The company faces cybersecurity threats that could disrupt operations or compromise sensitive data, potentially impacting financial condition and reputation.

• Charlie's Holdings, Inc. operates in the nicotine and nicotine alternative products market, including vapor products and synthetic nicotine products [S1].
• The company generated net revenue of approximately $20.9 million for the year ended December 31, 2025, and $7.8 million for the year ended December 31, 2024 [S1].
• Cash used in operating activities from continuing operations was approximately $6.3 million in 2025 and $2.0 million in 2024, indicating ongoing cash flow challenges [S1].
• The company relies on third-party contract manufacturers for commercial production as it has no internal manufacturing capacity [S1].
• Charlie's Holdings has submitted Premarket Tobacco Applications (PMTAs) for certain nicotine vapor products, including synthetic nicotine products marketed under the Pacha brand, and has received Marketing Denial Orders (MDOs) from the FDA, which are currently stayed pending judicial review [S1].
• The company faces significant regulatory risks related to FDA regulations, including the need for PMTA approvals to market products and potential impacts from flavor bans and other regulatory actions [S1].
• The company faces intense competition from larger, better-funded companies including 'big tobacco' and other vapor product manufacturers [S1].
• The company has approximately $10.8 million in current assets and $7.6 million in current liabilities as of December 31, 2025, resulting in a current ratio of 1.41 [S1].
• Net income for the year ended December 31, 2025 was approximately $4.5 million, with basic and diluted EPS of $0.02 per share [S1].
• The company completed a private offering in February 2026, issuing 3,550,000 shares of common stock at $0.20 per share, raising proceeds for working capital [S18].
• The company amended an asset purchase agreement with R.J. Reynolds Vapor Company in May 2025, selling additional synthetic nicotine products and related assets for $1.5 million [S21].
• The company faces risks related to product liability, cyber-security, regulatory compliance, and the ability to attract and retain key personnel [S1].
• The company has a limited trading market on the OTCQB Venture Market, with significant share dilution potential from outstanding preferred stock and options [S10, S13].
• The company’s products are subject to extensive federal, state, and local regulations, including FDA, FTC, DOJ, EPA, and others, which may increase compliance costs and affect product marketing and sales [S1].
• The company’s business outside the United States is subject to additional risks including tariffs, regulatory changes, and geopolitical events [S1].
• The company’s vapor products market is niche and evolving, with uncertain demand and acceptance [S1].
• The company’s financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.